QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,106 signal articles · 531 in last 24h · 103,813 total before filter · latest 23m ago
531last 24h
2507last 7d
477● bullish (7d)
255● bearish (7d)
197publishers
AllMacro231Earnings1481M&A143Regulatory15Product5Analyst29
✕ clear all filtersticker: GENBsentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Jersey Mike’s Is the Latest Stock Slide in Trading Debuts This Year
The Wall Street Journal5d agoneutral
Jersey Mike’s Is the Latest Stock Slide in Trading Debuts This Year

Jersey Mike’s Subs, with its 5.96% stock-price decline Thursday, is hardly alone in having a first-day share slide. This year, shares for hedge fund Pershing Square, nuclear fuel company Standard Nuclear and biotech firm Generate Biomedicines fell 18%, 18% and 21% respectively on their first trading days, according to Dealogic.

Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)
Insider Monkey42d agoneutral
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)

Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On May 14, Morgan Stanley increased its price objective on Generate Biomedicines, Inc. (NASDAQ:GENB) to $22 from $20. The firm maintained an “Overweight” rating on the shares. Separately, Generate Biomedicines, Inc. (NASDAQ:GENB)’s GB-0895 (anti-TSLP) program […]

A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent Gains
Simply Wall St.64d agoneutral
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent Gains

Recent trading snapshot and business context Generate Biomedicines (GENB) has drawn investor interest after a mixed stretch in the stock, with a small gain of 0.2% over the past day set against a decline of 9.7% over the past week. Over the past month the stock is roughly flat, while the past 3 months show a gain of 10.0%. This recent trading context sits alongside a market value of about US$1.68b and a share price of US$13.12 at the last close. See our latest analysis for Generate...

Generate Biomedicines (GENB) Valuation Check After Recent Share Price Weakness
Simply Wall St.150d agoneutral
Generate Biomedicines (GENB) Valuation Check After Recent Share Price Weakness

Generate Biomedicines: Recent Trading Moves And Core Business Snapshot Generate Biomedicines (GENB) has seen recent share price pressure, with a 10% decline over the past week and a similar move over the past month, bringing the latest close to US$11.21. For context, the company reports revenue of US$31.893 million alongside a net loss of US$249.523 million, reflecting the costs of developing its generative biology platform and early stage pipeline of protein based therapeutics. See our...